Evaluating a new PET imaging method for lung cancer
Test-retest Evaluation of [18F]F-AraG PET in Non-small Cell Lung Cancer (NSCLC) Patients
This study is testing a new PET imaging method to see how well it can measure the immune response in patients with advanced lung cancer.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CellSight Technologies, Inc. Industry-sponsored |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Iowa City, Iowa) |
| Trial ID | NCT06084806 on ClinicalTrials.gov |
What this trial studies
This pilot study evaluates the test-retest variability of [18F]F-AraG PET imaging in patients with advanced non-small cell lung cancer (NSCLC). Participants will undergo two PET scans within a week to measure the uptake of [18F]F-AraG in tumors and lymphoid tissue, aiming to assess the variability in physiological and measurement responses. The study is open-label and non-randomized, focusing on the potential of PET imaging to provide insights into the immune response to immunotherapy in NSCLC patients.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with histologically confirmed advanced NSCLC who are eligible for immunotherapy.
Not a fit: Patients with serious comorbidities, pregnant or nursing women, and those with severe claustrophobia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to monitor treatment responses in lung cancer patients undergoing immunotherapy.
How similar studies have performed: While PET imaging has been used in various contexts, this specific approach with [18F]F-AraG is novel and has not been extensively tested in this manner.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients (\>18 years old) with a histologically confirmed NSCLC and a candidate to receive immunotherapy as monotherapy or as combination therapy for advanced/metastatic disease. 2. Measurable disease. 3. ECOG performance status of 0, 1 or 2. Exclusion Criteria: 1. Serious comorbidities that in the opinion of the investigator/sponsor could compromise protocol objectives. 2. Pregnant women or nursing mothers. 3. Patients with severe claustrophobia.
Where this trial is running
Iowa City, Iowa
- University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States (Recruiting)
Study contacts
- Principal investigator: Muhammad Furqan, M.D. — Holden Comprehensive Cancer Center
- Study coordinator: Amy Mundisev
- Email: amy-mundisev@uiowa.edu
- Phone: 319-356-1445
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.